Ketogenic diet in women with polycystic ovary syndrome and liver dysfunction who are obese: A randomized, open‐label, parallel‐group, controlled pilot trial
Aim To evaluate the effect of a ketogenic diet (KD) in women with polycystic ovary syndrome (PCOS) and liver dysfunction who were obese. Methods Women with PCOS and liver dysfunction who were obese were enrolled in this prospective, open‐label, parallel‐group, controlled pilot trial, and randomly re...
Gespeichert in:
| Veröffentlicht in: | The journal of obstetrics and gynaecology research 2021-03, Vol.47 (3), p.1145-1152 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1152 |
|---|---|
| container_issue | 3 |
| container_start_page | 1145 |
| container_title | The journal of obstetrics and gynaecology research |
| container_volume | 47 |
| creator | Li, Jian Bai, Wen‐Pei Jiang, Bo Bai, Le‐Ran Gu, Bei Yan, Shu‐Xiang Li, Fu‐Ying Huang, Bin |
| description | Aim
To evaluate the effect of a ketogenic diet (KD) in women with polycystic ovary syndrome (PCOS) and liver dysfunction who were obese.
Methods
Women with PCOS and liver dysfunction who were obese were enrolled in this prospective, open‐label, parallel‐group, controlled pilot trial, and randomly received KD (KD group) or conventional pharmacological treatment (Essentiale plus Yasmin, control group) in a 1:1 ratio for 12 weeks. The primary endpoint was the liver function markers. Secondary endpoints included the menstrual cycle, anthropometric characteristics, body composition, hormonal levels, and metabolic biomarkers.
Results
Of the 20 eligible participants enrolled, 18 participants completed the study. The KD group reported a significant reduction in anthropometric characteristics and body composition from baseline to week 12 (all p |
| doi_str_mv | 10.1111/jog.14650 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2479042077</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2495139575</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3770-f3ea6d742b2814c10907d9922b8e1789c7ba0e96deeb4a38ef4dbd9d23c824f03</originalsourceid><addsrcrecordid>eNp1kctu1TAQhiMEohdY8ALIEhuQTlrfEsfsqgrKpVI3sI4ce3LqI8cOttMqrHiEPgLPxpNgOIUFEl7Yo5nv_zXyX1XPCD4h5ZzuwvaE8LbBD6pDwrmosWjah6VmnNQdFu1BdZTSDmMiJOkeVweM8ZZKjg-r7x8hhy14q5GxkJH16DZMUG6br9Ec3KrXlMs03Ki4orR6E8scKW-QszcQkVnTuHidbSii64BUBBQGSPAanaFYuDDZr2A2KMzgf3y7c2oAt0Gziso5cKWzjWGZN0gHn2MoPYNm60JGOVrlnlSPRuUSPL1_j6vPb998On9XX15dvD8_u6w1EwLXIwPVGsHpQDvCNcESCyMlpUMHRHRSi0FhkK0BGLhiHYzcDEYaynRH-YjZcfVy7zvH8GWBlPvJJg3OKQ9hST3lQmJOsRAFffEPugtL9GW7QsmGMNmIplCv9pSOIaUIYz9HO5VP7Anuf8VWVNv-d2yFfX7vuAwTmL_kn5wKcLoHbq2D9f9O_Yeri73lT4daphU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2495139575</pqid></control><display><type>article</type><title>Ketogenic diet in women with polycystic ovary syndrome and liver dysfunction who are obese: A randomized, open‐label, parallel‐group, controlled pilot trial</title><source>Access via Wiley Online Library</source><creator>Li, Jian ; Bai, Wen‐Pei ; Jiang, Bo ; Bai, Le‐Ran ; Gu, Bei ; Yan, Shu‐Xiang ; Li, Fu‐Ying ; Huang, Bin</creator><creatorcontrib>Li, Jian ; Bai, Wen‐Pei ; Jiang, Bo ; Bai, Le‐Ran ; Gu, Bei ; Yan, Shu‐Xiang ; Li, Fu‐Ying ; Huang, Bin</creatorcontrib><description>Aim
To evaluate the effect of a ketogenic diet (KD) in women with polycystic ovary syndrome (PCOS) and liver dysfunction who were obese.
Methods
Women with PCOS and liver dysfunction who were obese were enrolled in this prospective, open‐label, parallel‐group, controlled pilot trial, and randomly received KD (KD group) or conventional pharmacological treatment (Essentiale plus Yasmin, control group) in a 1:1 ratio for 12 weeks. The primary endpoint was the liver function markers. Secondary endpoints included the menstrual cycle, anthropometric characteristics, body composition, hormonal levels, and metabolic biomarkers.
Results
Of the 20 eligible participants enrolled, 18 participants completed the study. The KD group reported a significant reduction in anthropometric characteristics and body composition from baseline to week 12 (all p < 0.05). In addition, there were significant reductions in menstrual cycle, plasma estradiol, and progesterone levels in two groups (all p < 0.05), but no significant between‐group difference was observed. KD significantly reduced the liver function markers compared with control group (p < 0.05). The signs of fatty liver disappeared in six out of seven fatty liver participants in KD group after 12 weeks of intervention, while only one of 10 fatty liver participants in control group disappeared.
Conclusions
In addition to improving the menstrual cycle, KD had the additional benefits of reducing blood glucose and body weight, improving liver function, and treating fatty liver compared to traditional pharmacological treatment in women with PCOS and liver dysfunction who were obese.</description><identifier>ISSN: 1341-8076</identifier><identifier>EISSN: 1447-0756</identifier><identifier>DOI: 10.1111/jog.14650</identifier><identifier>PMID: 33462940</identifier><language>eng</language><publisher>Kyoto, Japan: John Wiley & Sons Australia, Ltd</publisher><subject>17β-Estradiol ; Body composition ; Body weight ; Drug therapy ; Fatty liver ; High fat diet ; Ketogenesis ; ketogenic diet ; Liver ; Liver diseases ; liver dysfunction ; Low carbohydrate diet ; Menstrual cycle ; Menstruation ; obesity ; Ovaries ; Polycystic ovary syndrome ; Progesterone</subject><ispartof>The journal of obstetrics and gynaecology research, 2021-03, Vol.47 (3), p.1145-1152</ispartof><rights>2021 Japan Society of Obstetrics and Gynecology</rights><rights>2021 Japan Society of Obstetrics and Gynecology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3770-f3ea6d742b2814c10907d9922b8e1789c7ba0e96deeb4a38ef4dbd9d23c824f03</citedby><cites>FETCH-LOGICAL-c3770-f3ea6d742b2814c10907d9922b8e1789c7ba0e96deeb4a38ef4dbd9d23c824f03</cites><orcidid>0000-0001-7667-6355</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjog.14650$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjog.14650$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33462940$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Jian</creatorcontrib><creatorcontrib>Bai, Wen‐Pei</creatorcontrib><creatorcontrib>Jiang, Bo</creatorcontrib><creatorcontrib>Bai, Le‐Ran</creatorcontrib><creatorcontrib>Gu, Bei</creatorcontrib><creatorcontrib>Yan, Shu‐Xiang</creatorcontrib><creatorcontrib>Li, Fu‐Ying</creatorcontrib><creatorcontrib>Huang, Bin</creatorcontrib><title>Ketogenic diet in women with polycystic ovary syndrome and liver dysfunction who are obese: A randomized, open‐label, parallel‐group, controlled pilot trial</title><title>The journal of obstetrics and gynaecology research</title><addtitle>J Obstet Gynaecol Res</addtitle><description>Aim
To evaluate the effect of a ketogenic diet (KD) in women with polycystic ovary syndrome (PCOS) and liver dysfunction who were obese.
Methods
Women with PCOS and liver dysfunction who were obese were enrolled in this prospective, open‐label, parallel‐group, controlled pilot trial, and randomly received KD (KD group) or conventional pharmacological treatment (Essentiale plus Yasmin, control group) in a 1:1 ratio for 12 weeks. The primary endpoint was the liver function markers. Secondary endpoints included the menstrual cycle, anthropometric characteristics, body composition, hormonal levels, and metabolic biomarkers.
Results
Of the 20 eligible participants enrolled, 18 participants completed the study. The KD group reported a significant reduction in anthropometric characteristics and body composition from baseline to week 12 (all p < 0.05). In addition, there were significant reductions in menstrual cycle, plasma estradiol, and progesterone levels in two groups (all p < 0.05), but no significant between‐group difference was observed. KD significantly reduced the liver function markers compared with control group (p < 0.05). The signs of fatty liver disappeared in six out of seven fatty liver participants in KD group after 12 weeks of intervention, while only one of 10 fatty liver participants in control group disappeared.
Conclusions
In addition to improving the menstrual cycle, KD had the additional benefits of reducing blood glucose and body weight, improving liver function, and treating fatty liver compared to traditional pharmacological treatment in women with PCOS and liver dysfunction who were obese.</description><subject>17β-Estradiol</subject><subject>Body composition</subject><subject>Body weight</subject><subject>Drug therapy</subject><subject>Fatty liver</subject><subject>High fat diet</subject><subject>Ketogenesis</subject><subject>ketogenic diet</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>liver dysfunction</subject><subject>Low carbohydrate diet</subject><subject>Menstrual cycle</subject><subject>Menstruation</subject><subject>obesity</subject><subject>Ovaries</subject><subject>Polycystic ovary syndrome</subject><subject>Progesterone</subject><issn>1341-8076</issn><issn>1447-0756</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kctu1TAQhiMEohdY8ALIEhuQTlrfEsfsqgrKpVI3sI4ce3LqI8cOttMqrHiEPgLPxpNgOIUFEl7Yo5nv_zXyX1XPCD4h5ZzuwvaE8LbBD6pDwrmosWjah6VmnNQdFu1BdZTSDmMiJOkeVweM8ZZKjg-r7x8hhy14q5GxkJH16DZMUG6br9Ec3KrXlMs03Ki4orR6E8scKW-QszcQkVnTuHidbSii64BUBBQGSPAanaFYuDDZr2A2KMzgf3y7c2oAt0Gziso5cKWzjWGZN0gHn2MoPYNm60JGOVrlnlSPRuUSPL1_j6vPb998On9XX15dvD8_u6w1EwLXIwPVGsHpQDvCNcESCyMlpUMHRHRSi0FhkK0BGLhiHYzcDEYaynRH-YjZcfVy7zvH8GWBlPvJJg3OKQ9hST3lQmJOsRAFffEPugtL9GW7QsmGMNmIplCv9pSOIaUIYz9HO5VP7Anuf8VWVNv-d2yFfX7vuAwTmL_kn5wKcLoHbq2D9f9O_Yeri73lT4daphU</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Li, Jian</creator><creator>Bai, Wen‐Pei</creator><creator>Jiang, Bo</creator><creator>Bai, Le‐Ran</creator><creator>Gu, Bei</creator><creator>Yan, Shu‐Xiang</creator><creator>Li, Fu‐Ying</creator><creator>Huang, Bin</creator><general>John Wiley & Sons Australia, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7667-6355</orcidid></search><sort><creationdate>202103</creationdate><title>Ketogenic diet in women with polycystic ovary syndrome and liver dysfunction who are obese: A randomized, open‐label, parallel‐group, controlled pilot trial</title><author>Li, Jian ; Bai, Wen‐Pei ; Jiang, Bo ; Bai, Le‐Ran ; Gu, Bei ; Yan, Shu‐Xiang ; Li, Fu‐Ying ; Huang, Bin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3770-f3ea6d742b2814c10907d9922b8e1789c7ba0e96deeb4a38ef4dbd9d23c824f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>17β-Estradiol</topic><topic>Body composition</topic><topic>Body weight</topic><topic>Drug therapy</topic><topic>Fatty liver</topic><topic>High fat diet</topic><topic>Ketogenesis</topic><topic>ketogenic diet</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>liver dysfunction</topic><topic>Low carbohydrate diet</topic><topic>Menstrual cycle</topic><topic>Menstruation</topic><topic>obesity</topic><topic>Ovaries</topic><topic>Polycystic ovary syndrome</topic><topic>Progesterone</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Jian</creatorcontrib><creatorcontrib>Bai, Wen‐Pei</creatorcontrib><creatorcontrib>Jiang, Bo</creatorcontrib><creatorcontrib>Bai, Le‐Ran</creatorcontrib><creatorcontrib>Gu, Bei</creatorcontrib><creatorcontrib>Yan, Shu‐Xiang</creatorcontrib><creatorcontrib>Li, Fu‐Ying</creatorcontrib><creatorcontrib>Huang, Bin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of obstetrics and gynaecology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Jian</au><au>Bai, Wen‐Pei</au><au>Jiang, Bo</au><au>Bai, Le‐Ran</au><au>Gu, Bei</au><au>Yan, Shu‐Xiang</au><au>Li, Fu‐Ying</au><au>Huang, Bin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ketogenic diet in women with polycystic ovary syndrome and liver dysfunction who are obese: A randomized, open‐label, parallel‐group, controlled pilot trial</atitle><jtitle>The journal of obstetrics and gynaecology research</jtitle><addtitle>J Obstet Gynaecol Res</addtitle><date>2021-03</date><risdate>2021</risdate><volume>47</volume><issue>3</issue><spage>1145</spage><epage>1152</epage><pages>1145-1152</pages><issn>1341-8076</issn><eissn>1447-0756</eissn><abstract>Aim
To evaluate the effect of a ketogenic diet (KD) in women with polycystic ovary syndrome (PCOS) and liver dysfunction who were obese.
Methods
Women with PCOS and liver dysfunction who were obese were enrolled in this prospective, open‐label, parallel‐group, controlled pilot trial, and randomly received KD (KD group) or conventional pharmacological treatment (Essentiale plus Yasmin, control group) in a 1:1 ratio for 12 weeks. The primary endpoint was the liver function markers. Secondary endpoints included the menstrual cycle, anthropometric characteristics, body composition, hormonal levels, and metabolic biomarkers.
Results
Of the 20 eligible participants enrolled, 18 participants completed the study. The KD group reported a significant reduction in anthropometric characteristics and body composition from baseline to week 12 (all p < 0.05). In addition, there were significant reductions in menstrual cycle, plasma estradiol, and progesterone levels in two groups (all p < 0.05), but no significant between‐group difference was observed. KD significantly reduced the liver function markers compared with control group (p < 0.05). The signs of fatty liver disappeared in six out of seven fatty liver participants in KD group after 12 weeks of intervention, while only one of 10 fatty liver participants in control group disappeared.
Conclusions
In addition to improving the menstrual cycle, KD had the additional benefits of reducing blood glucose and body weight, improving liver function, and treating fatty liver compared to traditional pharmacological treatment in women with PCOS and liver dysfunction who were obese.</abstract><cop>Kyoto, Japan</cop><pub>John Wiley & Sons Australia, Ltd</pub><pmid>33462940</pmid><doi>10.1111/jog.14650</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-7667-6355</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-8076 |
| ispartof | The journal of obstetrics and gynaecology research, 2021-03, Vol.47 (3), p.1145-1152 |
| issn | 1341-8076 1447-0756 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2479042077 |
| source | Access via Wiley Online Library |
| subjects | 17β-Estradiol Body composition Body weight Drug therapy Fatty liver High fat diet Ketogenesis ketogenic diet Liver Liver diseases liver dysfunction Low carbohydrate diet Menstrual cycle Menstruation obesity Ovaries Polycystic ovary syndrome Progesterone |
| title | Ketogenic diet in women with polycystic ovary syndrome and liver dysfunction who are obese: A randomized, open‐label, parallel‐group, controlled pilot trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A41%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ketogenic%20diet%20in%20women%20with%20polycystic%20ovary%20syndrome%20and%20liver%20dysfunction%20who%20are%20obese:%20A%20randomized,%20open%E2%80%90label,%20parallel%E2%80%90group,%20controlled%20pilot%20trial&rft.jtitle=The%20journal%20of%20obstetrics%20and%20gynaecology%20research&rft.au=Li,%20Jian&rft.date=2021-03&rft.volume=47&rft.issue=3&rft.spage=1145&rft.epage=1152&rft.pages=1145-1152&rft.issn=1341-8076&rft.eissn=1447-0756&rft_id=info:doi/10.1111/jog.14650&rft_dat=%3Cproquest_cross%3E2495139575%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2495139575&rft_id=info:pmid/33462940&rfr_iscdi=true |